ES2067744T3 - Aminas heterociclicas con actividad sobre el sistema nervioso central. - Google Patents

Aminas heterociclicas con actividad sobre el sistema nervioso central.

Info

Publication number
ES2067744T3
ES2067744T3 ES90908816T ES90908816T ES2067744T3 ES 2067744 T3 ES2067744 T3 ES 2067744T3 ES 90908816 T ES90908816 T ES 90908816T ES 90908816 T ES90908816 T ES 90908816T ES 2067744 T3 ES2067744 T3 ES 2067744T3
Authority
ES
Spain
Prior art keywords
sub
alkyl
activity
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90908816T
Other languages
English (en)
Inventor
Malcolm W Moon
Richard F Heier
Jeanette K Morris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ES2067744T3 publication Critical patent/ES2067744T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

COMPUESTOS CONTENIENDO NITROGENO TRICICLICO, CON ACTIVIDAD EN EL SISTEMA NERVIOSO CENTRAL DE FORMULA ESTRUCTURAL (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE R SUB 1, R SUB 2 Y R SUB 3 SON INDEPENDIENTEMENTE HIDROGENO, ALQUILO C SUB 1-6, ALQUENILO O ALQUINILO, CICLOALQUILO C SUB 3-10, O R SUB 1 Y R SUB 2 SE UNEN PARA FORMAR UNA AMINA CICLICA C SUB 3-7 QUE PUEDE CONTENER HETEROATOMOS ADICIONALES; X ES HIDROGENO, ALQUILO C SUB 1-6, HALOGENO, HIDROXI, ALCOXI, CIANO, CARBOXAMIDA, CARBOXILO, O CARBOALCOXILO; A ES SO SUB 2, N, CH, CH SUB 2, CHCH SUB 3, C = O, C = S, C-SCH SUB 3, C = NH, C-NH SUB 2, C-NHCH SUB 3, C-NHCOOCH SUB 3, O C-NHCN; B ES CH SUB 2, CH, C = O, N, NH O N-CH SUB 3; N ES 0 O 1; Y D ES CH, CH SUB 2, C = O, O, N, NH O N-CH SUB 3. ESTOS NUEVOS COMPUESTOS SON APROPIADOS PARA TRATAR LA ESQUIZOFRENIA, ENFERMEDAD DE PARKINSON, ANSIEDAD, DEPRESION O COMO COMPUESTOS PARA BAJAR LA PRESION SANGUINEA EN ANIMALES O RECEPTORES HUMANOS.
ES90908816T 1989-06-09 1990-05-15 Aminas heterociclicas con actividad sobre el sistema nervioso central. Expired - Lifetime ES2067744T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36437489A 1989-06-09 1989-06-09

Publications (1)

Publication Number Publication Date
ES2067744T3 true ES2067744T3 (es) 1995-04-01

Family

ID=23434241

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90908816T Expired - Lifetime ES2067744T3 (es) 1989-06-09 1990-05-15 Aminas heterociclicas con actividad sobre el sistema nervioso central.

Country Status (15)

Country Link
EP (1) EP0480939B1 (es)
JP (1) JP2955358B2 (es)
KR (1) KR0167346B1 (es)
AT (1) ATE117688T1 (es)
AU (1) AU626427B2 (es)
CA (1) CA2051697C (es)
DE (1) DE69016430T2 (es)
DK (1) DK0480939T3 (es)
ES (1) ES2067744T3 (es)
FI (2) FI96310C (es)
HK (1) HK65397A (es)
HU (2) HU210264B (es)
NO (1) NO301421B1 (es)
RU (1) RU2023712C1 (es)
WO (1) WO1990015058A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117276A (ja) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd 新規な３環性キノキサリンジオン誘導体
TW260660B (es) * 1993-04-22 1995-10-21 Sumitomo Pharma
DE4314593A1 (de) * 1993-04-28 1994-11-03 Schering Ag Pyrido(1,2,3-de)chinoxalinderivate, Verfahren zu deren Herstellung und ihre Verwendung von Arzneimitteln
KR100335548B1 (ko) * 1993-07-27 2002-10-04 파마시아 앤드 업존 캄파니 중추신경계활성을갖는헤테로사이클아민
FR2719843B1 (fr) * 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
EP0705834A1 (de) * 1994-07-27 1996-04-10 Ciba-Geigy Ag Azaaliphatisch Überbrückte Chinoxalin-2,3-dione
EP0705835A1 (de) * 1994-09-01 1996-04-10 Ciba-Geigy Ag Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
NZ315634A (en) * 1995-08-10 1998-11-25 Bayer Ag Halobenzimidazoles and their use as microbicides
US6288075B1 (en) 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
FR2760237B1 (fr) * 1997-02-28 1999-04-16 Rhone Poulenc Rorer Sa Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
FR2766487B1 (fr) * 1997-07-28 1999-08-27 Rhone Poulenc Rorer Sa Thiazolobenzoheterocycles, leur preparation et les medicaments les contenant
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
EP1149100A1 (en) * 1999-02-05 2001-10-31 PHARMACIA & UPJOHN COMPANY PROCESS TO PREPARE (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO 4,5,1-ij]-QUINOLIN-2(1H)-ONE
US7074927B2 (en) 1999-05-13 2006-07-11 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
DE19954707A1 (de) 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazolverbindungen als Phosphodiesterase VII-Hemmer
GB0008939D0 (en) * 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
ES2253370T3 (es) 2000-04-21 2006-06-01 PHARMACIA & UPJOHN COMPANY LLC Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica.
AR033520A1 (es) * 2000-04-27 2003-12-26 Upjohn Co (5r)-(metilamino) -5,6-dihidro-4h-imidazo[4,5,1-ij] quinolin-2(1h)-tiona
MXPA03001472A (es) 2000-08-16 2003-06-06 Upjohn Co Compuestos para el tratamiento de trastornos adictivos.
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031202A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
DE60216457T2 (de) * 2001-02-27 2007-09-20 Ortho-Mcneil Pharmaceutical, Inc. Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
WO2004037971A2 (en) * 2002-10-25 2004-05-06 Pharmacia & Upjohn Company Llc Use of heterocyclic amine-type compounds as neuroprotective agents
US7262297B2 (en) * 2003-05-15 2007-08-28 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
BRPI0413132A (pt) * 2003-07-31 2006-10-03 Irm Llc composições e compostos bicìclicos como inibidores de pdf
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
PH12012501282A1 (en) 2004-08-13 2019-03-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0513848A (pt) 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de pélete de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável deste, método para fabricação da mesma e uso desta
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
TW200635926A (en) * 2004-11-05 2006-10-16 Wyeth Corp Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof
AR053902A1 (es) 2005-06-14 2007-05-23 Schering Corp Inhibidores de aspartil proteasa heterociclicos macrociclicos
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
PE20150777A1 (es) 2012-09-14 2015-06-20 AbbVie Deutschland GmbH and Co KG Derivados triciclicos de quinolinas y de quinoxalinas

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989010741A1 (en) * 1988-05-09 1989-11-16 The Upjohn Company Anxiolytic/anti-depressant 2,3-dihydro-1h-phenalen-2-amines

Also Published As

Publication number Publication date
NO301421B1 (no) 1997-10-27
AU626427B2 (en) 1992-07-30
FI944704A0 (fi) 1994-10-07
DK0480939T3 (da) 1995-07-10
ATE117688T1 (de) 1995-02-15
EP0480939B1 (en) 1995-01-25
FI96687B (fi) 1996-04-30
CA2051697A1 (en) 1990-12-10
HK65397A (en) 1997-05-23
KR920701204A (ko) 1992-08-11
RU2023712C1 (ru) 1994-11-30
FI915715A0 (fi) 1991-12-04
JPH04506071A (ja) 1992-10-22
HU210264B (en) 1995-03-28
AU5743890A (en) 1991-01-07
HU211702A9 (en) 1995-12-28
NO914827L (no) 1992-02-07
FI96687C (fi) 1996-08-12
FI96310B (fi) 1996-02-29
WO1990015058A1 (en) 1990-12-13
HU905216D0 (en) 1992-02-28
DE69016430T2 (de) 1995-06-01
NO914827D0 (no) 1991-12-06
FI944704L (fi) 1994-10-07
JP2955358B2 (ja) 1999-10-04
CA2051697C (en) 1996-10-08
DE69016430D1 (de) 1995-03-09
HUT60269A (en) 1992-08-28
EP0480939A1 (en) 1992-04-22
KR0167346B1 (ko) 1999-01-15
FI96310C (fi) 1996-06-10

Similar Documents

Publication Publication Date Title
ES2067744T3 (es) Aminas heterociclicas con actividad sobre el sistema nervioso central.
AR004516A1 (es) Derivados de pirimidina, su uso, procedimientos para prepararlos y medicamentos que los contienen
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
ES2119124T3 (es) Bencimidazoles utiles para el tratamiento de trastornos del sistema nervioso.
CL2003002050A1 (es) Compuestos derivados de 1-piperazin-1,2-dihidroindeno, su composicion farmaceutica y el uso de esta para tratar enfermedades del sistema nervioso central.
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
AR016817A1 (es) Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
PE20030759A1 (es) Uso de ureas de benzotiazoles
AR030533A1 (es) Compuestos derivados de biarileter utiles como inhibidores de la recaptacion de monoaminas, composicion farmaceutica, procedimiento de tratamiento intermediario
PT89110A (pt) Processo de preparacao de derivados da quinazolina e de composicoes farmaceuticas que os contem
CO4410321A1 (es) Compuestos ciclicos condensados con funciones aminoacidas sustituidas y derivados ester de los mismos
ES2062009T4 (es) Agentes antifungicos derivados de triazol
ES2175161T3 (es) Derivados de piperazina como antagonistas de taquiquinina.
ES2163071T3 (es) Sulfonamidas y su utilizacion.
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
MX9307940A (es) Nuevos derivados de la imidazopiridina, proceso para su preparacion y formulaciones farmaceuticas que los incluyen
ES2157224T3 (es) Derivados de 5-arilindol y su uso como agonistas de serotonina (5-ht 1).
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
SV2002000022A (es) Inhibidores de recanalizacion de la monoamida para el tratamiento de los desordenes del sistema nervioso central ref. pc10434
ATE247639T1 (de) Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
ES2150671T3 (es) Compuesto de bencimidazol y su utilizacion como moduladores del complejo de receptores gaba-a.
PE20030867A1 (es) Derivados de quinazolinona
AR028475A1 (es) Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 480939

Country of ref document: ES